Molecular and immunological basis of X-linked lymphoproliferative disease

Immunological Reviews

Volumn 192, Issue , 2003, Pages 212-224

  Latour, Sylvain ^a   Veillette, André ^b,c,d  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

^d MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN; PROTEIN SLAP; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; TYROSINE; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; CLINICAL FEATURE; CYTOPLASM; EPSTEIN BARR VIRUS; GENE MUTATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SRC HOMOLOGY DOMAIN; X LINKED LYMPHOPROLIFERATIVE DISEASE;

AMINO ACID SEQUENCE; ANTIGENS, CD; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOPROLIFERATIVE DISORDERS; MODELS, IMMUNOLOGICAL; MOLECULAR SEQUENCE DATA; RECEPTORS, CELL SURFACE;

EID: 0038578604     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2003.00023.x     Document Type: Review

References (81)

1. Sayos J, et al. The X-linked lymphoproliferative-disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature 1998;395:462-469.
2. Nichols KE, et al. Inactivating mutations in an SH2 domain-encoding gene in X-linked lymphoproliferative syndrome. Proc Natl Acad Sci USA 1998;95:13765-13770.
3. Coffey AJ, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet 1998;20:129-135.
4. Morra M, et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. Annu Rev Immunol 2001;19:657-682.
5. Veillette A. The SAP family: a new class of adaptor-like molecules that regulates immune cell functions. Sci STKE 2002:E8.
6. Purtilo DT, Cassel CK, Yang JP, Harper R. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease). Lancet 1975;1:935-940.
7. Seemayer TA, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res 1995;38:471-478.
8. Morra M, et al. Alterations of the X-linked lymphoproliferative disease gene SH2D1A in common variable immunodeficiency syndrome. Blood 2001;98:1321-1325.
9. Wu C, et al. SAP controls T cell responses to virus and terminal differentiation of Th2 cells. Nat Immunol 2001;2:410-414.
10. Czar MJ, et al. Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci USA 2001;98:7449-7454.
11. Argov S, Johnson DR, Collins M, Koren HS, Lipscomb H, Purtilo DT. Defective natural killing activity but retention of lymphocyte-mediated antibody-dependent cellular cytotoxicity in patients with the X-linked lymphoproliferative syndrome. Cell Immunol 1986;100:1-9.
12. Harada S, Bechtold T, Seeley JK, Purtilo DT. Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)-cell activity in the X-linked lymphoproliferative syndrome. Int J Cancer 1982;30:739-744.
13. Sullivan JL, Byron KS, Brewster FE, Purtilo DT. Deficient natural killer cell activity in X-linked lymphoproliferative syndrome. Science 1980;210:543-545.
14. de Saint Basile G, Fischer A. The role of cytotoxicity in lymphocyte homeostasis. Curr Opin Immunol 2001;13:549-554.
15. Thompson AD, et al. EAT-2 is a novel SH2 domain containing protein that is upregulated by Ewing's sarcoma EWS/FLI1 fusion gene. Oncogene 1996;13:2649-2658.
16. Morra M, et al. Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells. EMBO J 2001;20:5840-5852.
17. Morra M, et al. Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem 2001;276:36809-36816.
18. Sumegi J, et al. Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. Blood 2000;96:3118-3125.
19. Brandan O, et al. Epstein-Barr virus-negative boys with non-Hodgkin lymphoma are mutated in the SH2D1A gene, as are patients with X-linked lymphoproliferative disease (XLP). Hum Mol Genet 1999;8:2407-2413.
20. Poy F, et al. Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol Cell 1999;4:555-561.
21. Hwang PM, et al. A 'three-pronged' binding mechanism for the SAP/SH2D1A SH2 domain: structural basis and relevance to the XLP syndrome. EMBO J 2002;21:314-323.
22. Li SC, et al. Novel mode of ligand binding by the SH2 domain of the human XLP disease gene product SAP/SH2D1A. Curr Biol 1999;9:1355-1362.
23. Latour S, Gish G, Helgason CD, Humphries RK, Pawson T, Veillette A. Regulation of SLAM-mediated signal transduction by SAP, the X-linked lymphoproliferative gene product. Nat Immunol 2001;2:681-690.
24. Cocks BG, Chang CC, Carballido JM, Yssel H, de Vries JE, Aversa G. A novel receptor involved in T-cell activation. Nature 1995;376:260-263.
25. Mathew PA, et al. Cloning and characterization of the 2B4 gene encoding a molecule associated with non-MHC-restricted killing mediated by activated natural killer cells and T cells. J Immunol 1993;151:5328-5237.
26. de la Fuente MA, et al. Molecular characterization and expression of a novel human leukocyte cell-surface marker homologous to mouse Ly-9. Blood 2001;97:3513-3520.
27. de la Fuente MA, Pizcueta P, Nadal M, Bosch J, Engel P. CD84 leukocyte antigen is a new member of the Ig superfamily. Blood 1997;90:2398-2405.
28. Bottino C, et al. NTB-A, a novel SH2D1A-associated surface molecule contributing to the inability of natural killer cells to kill Epstein-Barr virus-infected B cells in X-linked lymphoproliferative disease. J Exp Med 2001;194:235-246.
29. Bouchon A, Cella M, Grierson HL, Cohen JI, Colonna M. Cutting edge: activation of NK cell-mediated cytotoxicity by a SAP-independent receptor of the CD2 family. J Immunol 2001;167:5517-5521.
30. Tangye SG, Phillips JH, Lanier LL. The CD2-subset of the Ig superfamily of cell surface molecules: receptor-ligand pairs expressed by NK cells and other immune cells. Semin Immunol 2000;12:149-157.
31. Parolini S, et al. X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells. J Exp Med 2000;192:337-346.
32. Tangye SG, Phillips JH, Lanier LL, Nichols KE. Functional requirement for SAP in 2B4-mediated activation of human natural killer cells as revealed by the X-linked lymphoproliferative syndrome. J Immunol 2000;165:2932-2936.
33. Tangye SG, Lazetic S, Woollatt E, Sutherland GR, Lanier LL, Phillips JH. Cutting edge: human 2B4, an activating NK cell receptor, recruits the protein tyrosine phosphatase SHP-2 and the adaptor signaling protein SAP. J Immunol 1999;162:6981-6985.
34. Sayos J, et al. Cell surface receptors Ly-9 and CD84 recruit the X-linked lymphoproliferative disease gene product SAP. Blood 2001;97:3867-3874.
35. Baker JE, Majeti R, Tangye SG, Weiss A. Protein tyrosine phosphatase CD148-mediated inhibition of T-cell receptor signal transduction is associated with reduced LAT and phospholipase Cgamma1 phosphorylation. Mol Cell Biol 2001;21:2393-2403.
36. Fraser CC, et al. Identification and characterization of SF2000 and SF2001, two new members of the immune receptor SLAM/CD2 family. Immunogenetics 2002;53:843-850.
37. Kingsbury GA, et al. Cloning, expression, and function of BLAME, a novel member of the CD2 family. J Immunol 2001;166:5675-5680.
38. Fennelly JA, Tiwari B, Davis SJ, Evans EJ. CD2F-10: a new member of the CD2 subset of the immunoglobulin superfamily. Immunogenetics 2001;53:599-602.
39. Punnonen J, et al. Soluble and membrane-bound forms of signaling lymphocytic activation molecule (SLAM) induce proliferation and Ig synthesis by activated human B lymphocytes. J Exp Med 1997;185:993-1004.
40. Mavaddat N, et al. Signaling lymphocytic activation molecule (CDw 150) is homophilic but self-associates with very low affinity. J Biol Chem 2000;275:28100-28109.
41. Martin M, et al. CD84 functions as a homophilic adhesion molecule and enhances IFN-gamma secretion: adhesion is mediated by Ig-like domain 1. J Immunol 2001;167:3668-3676.
42. Kumaresan P, Lai W, Chuang S, Bennett M, Mathew P. CS1, a novel member of the CD2 family, is homophilic and regulates NK cell function. Mol Immunol 2002;39:1.
43. Latchman Y, McKay PF, Reiser H. Identification of the 2B4 molecule as a counter-receptor for CD48. J Immunol 1998;161:5809-5812.
44. Hsu EC, Iorio C, Sarangi F, Khine AA, Richardson CD. CDw150 (SLAM) is a receptor for a lymphotropic strain of measles virus and may account for the immunosuppressive properties of this virus. Virology 2001;279:9-21.
45. Tatsuo H, Ono N, Tanaka K, Yanagi Y. SLAM (CDw150) is a cellular receptor for measles virus. Nature 2000;406:893-897.
46. Nakajima H, et al. Patients with X-linked lymphoproliferative disease have a defect in 2B4 receptor-mediated NK cell cytotoxicity. Eur J Immunol 2000;30:3309-3318.
47. Latour S, et al. Binding of SAP SH2 domain to FynT SH3 domain reveal a novel mechanism of receptor signalling in immune regulation. Nat Cell Biol (in press).
48. Olszowy, MW, Leuchtmann, PL, Veillette, A, Shaw, AS. Comparison of p56lck and p59fyn protein expression in thymocyte subsets, peripheral T cells, NK cells, and lymphoid cell lines. J Immunol 1995;155:4236-4240.
49. Appleby MW, Gross JA, Cooke MP, Levin SD, Qian X, Perlmutter RM. Defective T cell receptor signaling in mice lacking the thymic isoform of p59fyn. Cell 1992;70:751-763.
50. Stein PL, Lee HM, Rich S, Soriano P. pp59fyn mutant mice display differential signaling in thymocytes and peripheral T cells. Cell 1992;70:741-750.
51. Fukai I, Hussey RE, Sunder-Plassmann R, Reinherz EL. A critical role for p59(fyn) m CD2-based signal transduction. Eur J Immunol 2000;30:3507-3515.
52. Appleby MW, et al. Involvement of p59fynT in interleukin-5 receptor signaling. J Exp Med 1995;182:811-820.
53. Gadue P, Morton N, Stein PL. The Src family tyrosine kinase Fyn regulates natural killer T cell development. J Exp Med 1999;190:1189-1196.
54. Eberl G, Lowin-Kropf B, MacDonald HR. Cutting edge: NKT cell development is selectively impaired in Fyn- deficient mice. J Immunol 1999;163:4091-4094.
55. Parravicini V, et al. Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nat Immunol 2002;3:741-748.
56. Castro AG, et al. Molecular and functional characterization of mouse signaling lymphocytic activation molecule (SLAM): differential expression and responsiveness in Th1 and Th2 cells. J Immunol 1999;163:5860-5870.
57. Kruse M, et al. Signaling lymphocytic activation molecule is expressed on mature CD83(+) dendritic cells and is up-regulated by IL-1beta. J Immunol 2001;167:1989-1995.
58. Bleharski JR, Niazi KR, Sieling PA, Cheng G, Modlin RL. Signaling lymphocytic activation molecule is expressed on CD40 ligand-activated dendritic cells and directly augments production of inflammatory cytokines. J Immunol 2001;167:3174-3181.
59. Howie D, et al. The role of SAP in murine CD150 (SLAM)-mediated T-cell proliferation and interferon gamma production. Blood 2002;100:2899-2907.
60. Carballido JM, et al. Reversal of human allergic T helper 2 responses by engagement of signaling lymphocytic activation molecule. J Immunol 1997;159:4316-4321.
61. Aversa G, Chang CC, Carballido JM, Cocks BG, de Vries JE. Engagement of the signaling lymphocytic activation molecule (SLAM) on activated T cells results in IL-2-independent, cyclosporin A-sensitive T cell proliferation and IFN-gamma production. J Immunol 1997;158:4036-4044.
62. Krystal G. Lipid phosphatases in the immune system. Semin Immunol 2000;12:397-403.
63. Schneider H, Guerette B, Guntermann C, Rudd CE. Resting lymphocyte kinase (Rlk/Txk) targets lymphoid adaptor SLP-76 in the cooperative activation of interleukin-2 transcription in T-cells. J Biol Chem 2000;275:3835-3840.
64. Schaeffer EM, et al. Requirement for Tec kinases Rlk and Itk in T cell receptor signaling and immunity. Science 1999;284:638-641.
65. Hu Q, et al. Identification of Rlk, a novel protein tyrosine kinase with predominant expression in the T cell lineage. J Biol Chem 1995;270:1928-1934.
66. Schaeffer EM, et al. Mutation of Tec family kinases alters T helper cell differentiation. Nat Immunol 2001;2:1183-1188.
67. Kane LP, Andres PG, Howland KC, Abbas AK, Weiss A. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat Immunol 2001;2:37-44.
68. Valiante NM, Trinchieri G. Identification of a novel signal transduction surface molecule on human cytotoxic lymphocytes. J Exp Med 1993;178:1397-1406.
69. Speiser DE, et al. The activatory receptor 2B4 is expressed in vivo by human CD8+ effector alphabeta T cells. J Immunol 2001;167:6165-6170.
70. Garni-Wagner BA, Purohit A, Mathew PA, Bennett M, Kumar V. A novel function-associated molecule related to non-MHC-restricted cytotoxicity mediated by activated natural killer cells and T cells. J Immunol 1993;151:60-70.
71. Moretta A, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001;19:197-223.
72. Watzl C, Stebbins CC, Long EO. NK cell inhibitory receptors prevent tyrosine phosphorylation of the activation receptor 2B4 (CD244). J Immunol 2000;165:3545-3548.
73. Aoukaty A, Tan R. Association of the X-linked lymphoproliferative disease gene product SAP/SH2D1A with 2B4, a natural killer cell-activating molecule, is dependent on phosphoinositide 3-kinase. J Biol Chem 2002;277:13331-13337.
74. Klem J, Verrett PC, Kumar V, Schatzle JD. 2B4 is constitutively associated with linker for the activation of T cells in glycolipid-enriched microdomains: properties required for 2B4 lytic function. J Immunol 2002;169:55-62.
75. Chuang SS, Kumaresan PR, Mathew PA. 2B4 (CD244)-mediated activation of cytotoxicity and IFN-gamma release in human NK cells involves distinct pathways. J Immunol 2001;167:6210-6216.
76. Bottino C, et al. Analysis of the molecular mechanism involved in 2B4-mediated NK cell activation: evidence that human 2B4 is physically and functionally associated with the linker for activation of T cells. Eur J Immunol 2000;30:3718-3722.
77. Benoit L, Wang X, Pabst HF, Dutz J, Tan R. Defective NK cell activation in X-linked lymphoproliferative disease. J Immunol 2000;165:3549-3553.
78. Sivori S, et al. Early expression of triggering receptors and regulatory role of 2B4 in human natural killer cell precursors undergoing in vitro differentiation. Proc Natl Acad Sci USA 2002;99:4526-4531.
79. Kambayashi T, Assarsson E, Chambers BJ, Ljunggren HG. Cutting edge: regulation of CD8(+) T cell proliferation by 2B4/CD48 interactions. J Immunol 2001;167:6706-6710.
80. Peck SR, Ruley HE. Ly108: a new member of the mouse CD2 family of cell surface proteins. Immunogenetics 2000;52:63-72.
81. Tangye SG, van de Weerdt BC, Avery DT, Hodgkin PD. CD84 is up-regulated on a major population of human memory B cells and recruits the SH2 domain containing proteins SAP and EAT-2. Eur J Immunol 2002;32:1640-1649.